structure, lacrimal glands, adipose tissue, neural tissue, and mature cartilage. [2, 3] The choristoma in the right eye was excised and scleral grafting was performed as choristoma was involving more of scleral side. Other ocular findings which may be present with LNSS are eyelid colobomas and masses, ptosis, nystagmus, strabismus, corneal vascularization, microphthalmia, macrophthalmia, iris coloboma, cataract, chorioretinal coloboma, staphyloma, optic disc coloboma, optic nerve glioma, pseudopapilloedema, choroidal osteoma, and cortical visual impairment. Our case had unilateral limbal choristoma, posterior staphyloma, and chorioretinal coloboma over superotemporal arcade and left eye showed megalocornea and nevus over temporal limbus. Also compound melanocytic nevus involving periocular region of face was noted which was purely coincidental finding.
Nevus sebaceous may be associated with malignancy. Therefore, these patients must be monitored closely. In our patient, the nevus sebaceous has shown no evidence of malignant transformation till 1 year of follow-up examinations. Patchy alopecia was also observed in our case [ Fig. 4 ]. Neurological abnormalities, seizures and mental retardation, quadriparesis, microcephaly, and diencephalic syndrome may be observed in LNSS patients. But, our patient had no history of developmental delay and convulsion and no evidence of mental retardation.
Corneal grafting was tried in these patients but no encouraging results found due to graft vascularization. [4] Amniotic membrane transplant was also tried after excision of complex limbal choristoma for surface reconstruction. [5] Complex choristomas are usually deep and scleral grafting may be required to achieve the anatomical integrity. We have done scleral graft in our patient, which has proved to be promising. treat various types of neovascular diseases.
Though not formally studied or approved for any intraocular disease, the high cost and unavailability of a related ocular drugs pegaptanib and ranibizumab led to rapid and wide use of bevacizumab all over the world. [1] The suggested intravitreal dose of avastin is 1.25 mg (0.05 ml). As bevacizumab is a chemotherapeutic agent, it comes from the manufacturer in a 4-ml vial. Both in order to reduce waste as well as cost, multiple doses are aliquoted from the vial.
The purpose of the study was to assess the risk of endophthalmitis following multiple intravitreal injections of bevacizumab from single use vial.
Materials and Methods
We administered intravitreal bevacizumab injection to eight eyes of eight patients of various etiologies ranging from retinal vein occlusion to diabetic retinopathy, age related macular degeneration AMD, and choroidal neovascular membrane CNVM. The best corrected visual acuity of seven out of eight patients was poor and ranged from 20/120 to finger counting. Only one patient had good visual acuity of 20/40 [ Table 1 ]. The details of the procedure, complications were discussed with the patients, and written consent taken. All patients were called on the same day to eye OT. Injection bevacizumab was procured by a patient five days prior to the date of appointment and stored under recommended conditions (i.e., below 4°C). On the day of injection, under aseptic precautions, the vial was opened in operation theatres, hood was not used due to its nonavailability. 0.05 ml of drug was withdrawn into a 1-ml tuberculin syringe. The syringe was then capped with a 30-gauge needle and kept on a sterile tray.
The eye of each patient was prepared following standard aseptic procedures (i.e., lids cleaned sequentially first with spirit and then with 10% povidone-iodine). Topical anesthesia was given by instilling 0.5% proparacaine hydrochloride drops 2-3 times. Fornices were flushed with normal saline and 1 drop of 10% povidone-iodine was instilled 2 min before the procedure.
Intravitreal bevacizumab injection was administered into the superotemporal quadrant, 4 mm from the limbus. Eye was patched and patient was sent home.
The same procedure was followed sequentially for all patients. Different needles were used each time after cleaning the surface of vial with spirit, thereby administering multiple pricks in the vial. The procedure was uneventful. The remaining drug was kept under recommended conditions in refrigerator for future use. All of them were asked to come next week for follow-up or earlier if patient experienced severe discomfort.
Four of the eight patients reported to the hospital on the 3rd day after injection with complaints of pain, watering, and diminution of vision. Two patients reported the following day with similar complaints. Two patients who did not report by the 4th day were contacted and recalled for an examination. All the patients were thoroughly examined using slit lamp biomicroscopy and indirect ophthalmoscopy. Six out of eight patients had absent fundal glow along with presence of cells and flares [ Table 2 ].
These six patients were clinically diagnosed to have endophthalmitis and were administered intravitreal antibiotics (injection ceftazidime 2.25 mg in 0.1 ml and injection vancomycin 1 mg in 0.1 ml) on the same day of presentation. Remaining two patients who were recalled did not develop endophthalmitis. Vitreous samples and drug vial were sent for culture sensitivity in two different laboratories which turned out to be sterile. Conc. antibiotic drops and cycloplegics were continued topically. Intravitreal antibiotics were repeated after 48 h. All patients were closely followed up and remaining drug was discarded. Five of six patients who developed endophthalmitis showed response to treatment.
Discussion
While pegaptanib and ranibizumab are labeled for intravitreal use, bevacizumab is labeled for use in cancer therapy and is currently being used "off-label" for the treatment of ocular neovascular diseases. Because of its "off-label" use, bevacizumab is supplied in much larger volumes than those needed for single intravitreal injection. Thus, hospitals and compounding pharmacies must divide the larger volume of bevacizumab into smaller units suitable for single-use, individual doses. Contaminants could possibly be introduced during the compounding process and compromise the sterility of the aliquoted drug. [2] Multiple pricks (procedure common in India) were made in vial to prepare administrating dose for eight patients. This compounding process could be the reason for cluster endophthalmitis. An alternative protocol suggested is that small aliquot of drug should be prepared using single prick technique, i.e., 0.5 in. 26 gauge needle should be inserted into rubber cap of vial and drug should be drawn into different 1 ml syringes, every time changing only the syringe, leaving the needle in place. These syringes should be stored under aseptic conditions. Patients should be called in small groups of two or three for intravitreal injection. Next group should be administered injection after one week, i.e., after the first follow-up of the previous batch. In this way, we would be able to minimize incidence of cluster endophthalmitis and detect possible contamination in the compounded aliquoted drug before it is administered to the next batch. For the same reason bilateral intravitreal injection should be avoided. If required, each eye should be injected using drug from different lots under sterile conditions. We were able to minimize the incidence of cluster endophthalmitis using alternative protocol.
Six out of eight patients had endophthalmitis, remaining two patients though belonging to different age groups (50 and 72 years), did not develop endophthalmitis. The possible reason for this could be the inherent immunity against the causative organism or the quantity of causative organism in the inoculums could have been below the threshold required for endophthalmitis.
Presentation of cases with signs and symptoms of endophthalmitis and response with intravitreal injection of antibiotics led us to assume infective pathology despite the negative culture report. Four out of five cases in MARINA study were also culture negative. [3] The possibility of TASS syndrome in these patients was considered, but review of literature suggests that series of patients, who developed TASS syndrome in Canada, had reported as early as 24 h. The final visual outcome was poor even with aggressive treatment. All patients had worse visual acuity at the end of follow-up than on injection day. [4] Four patients in our study presented on day 3, while two patients reported on day 4, after intravitreal injection. Three out six patients with endophthalmitis showed improvement in visual acuity with intravitreal antibiotic therapy, as compared to pretreatment level. Visual acuity remained same in two Table 3 ].
Conclusion
As the approval of intravitreal use of bevacizumab and its subsequent availability in the market in single dose (0.05 ml ampoules) is still awaited, using the single-dose vial and aliquoting into smaller doses for multiple uses, is the call of the day. However, the present incident highlights the risks of microbial contamination and the need to stay vigilant against preexisting contamination within the vial or its access to the drug via multiple pricks.
